REVENUE (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) segment	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Number of reportable segments | segment			2
Total revenue, net	$ 31,237	$ 30,955	$ 88,894	$ 93,381
Contract receivables, current	1,000		1,000		$ 900
Contract receivables, noncurrent	3,600		3,600		3,300
Current portion of deferred revenue, and other	8,700		8,700		9,600
Contract liabilities, revenue recognized			2,100
Contract liabilities, increase due to additional deferred sales			$ 1,200
Average term of underlying contracts			P6Y0M0D
Capitalized contract costs	2,600		$ 2,600		$ 2,500
Capitalized contract costs, amortization			700
Capitalized contract costs during the period			900
Core companion animal
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	26,339	27,190	75,771	80,652
Point of Care laboratory revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	17,524	14,584	49,605	43,277
Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	14,021	11,598	39,545	33,942
Sales-type leases
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,587	1,228	4,821	4,559
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,547	1,382	4,122	3,528
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	369	376	1,117	1,248
Point of Care imaging revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	5,337	5,326	15,976	15,759
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,479	4,453	13,431	13,157
Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	544	590	1,663	1,689
Operating type leases and other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	314	283	882	913
Other CCA revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,478	7,280	10,190	21,616
Other pharmaceuticals, vaccines and diagnostic tests
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,400	7,176	9,927	21,278
Research and development, license and royalty revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	78	104	263	338
Other vaccines and pharmaceuticals
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,898	3,765	13,123	12,729
Contract manufacturing
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,747	3,540	12,741	12,218
License, research and development
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	$ 151	$ 225	$ 382	$ 511